Vejledninger og FAQtaark

Indholdsfortegnelse

Udskriv denne side
Print kapitel

Referencer

  1. Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K, Steering Group of the National Diabetes R. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51(12):2187-96.
  2. World Health Organization. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva, 2011.
  3. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva, 1999.
  4. Sundhedsstyrelsen. Notat vedrørende diagnostik af diabetes mellitus med HbA1c: Sundhedsstyrelsen; 2012 [Available from: https://www.sst.dk/da/~/~/media/2A3178A6D31B428FA888E39AA46B0B4E.ashx.
  5. Helsedirektoratet. Nasjonal faglig retningslinje for diabetes 2017 [Available from: https://helsedirektoratet.no/retningslinjer/diabetes.
  6. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413-20.
  7. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800-11.
  8. Lauritzen T, Sandbaek A, Skriver MV, Borch-Johnsen K. HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark. Diabetologia. 2011;54(6):1318-26.
  9. Sundhedsstyrelsen. Anbefalinger for forebyggelsestilbud til borgere med kronisk sygdom. København: Sundhedsstyrelsen; 2016.
  10. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035-87.
  11. American Diabetes Association. Standards of medical care in diabetes-2017 Diabetes Care. 2017;40(Suppl. 1).
  12. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069-78.
  13. Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res. 2002;53(6):1053-60.
  14. Ciechanowski PS, Katon WJ, Russo JE, Hirsch IB. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry. 2003;25(4):246-52.
  15. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications. 2005;19(2):113-22.
  16. Ribe AR, Laursen TM, Sandbaek A, Charles M, Nordentoft M, Vestergaard M. Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. Psychol Med. 2014;44(14):3097-107.
  17. Kristensen JK, Bak JF, Wittrup I, Lauritzen T. Diabetes prevalence and quality of diabetes care among Lebanese or Turkish immigrants compared to a native Danish population. Prim Care Diabetes. 2007;1(3):159-65.
  18. Singhammer J. Etniske minoriteters sundhed. Center for Folkesundhed, Region Midtjylland; 2008.
  19. Folmann N, Jørgensen T. Etniske minoriteter-sygdom og brug af sundhedsvæsnet: Et registerstudie. 2006.
  20. Wittrup I, Kristensen JK. Diabeteskole for etniske minoriteter i nærmiljøet. 2008.
  21. Uggerly S, Mandrup G, Melgaard K, Abdalla K, Sonne S, Jacobsen T, et al. Maden hos indvandrere og flytninge i Danmark (The Food among Immigrants and Refugees in Denmark). Copenhagen: National Food Institute [in Danish]. 2002.
  22. Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ. 2001;323(7319):970-5.
  23. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54(3):603-8.
  24. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374-83.
  25. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ. 1993;306(6888):1313-8.
  26. Corradi L, Zoppi A, Tettamanti F, Malamani G, Lazzari P, Fogari R. Association between smoking and micro-albuminuria in hypertensive patients with type 2 diabetes mellitus. J Hypertens Suppl. 1993;11(5):S190-1.
  27. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456-61.
  28. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-44.
  29. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278(21):1759-66.
  30. Clair C, Rigotti NA, Porneala B, Fox CS, D'Agostino RB, Pencina MJ, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309(10):1014-21.
  31. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med. 1991;324(11):739-45.
  32. Agerholm A, Bukholt SE, Golubovic S, Hansson L, Ibsen JR, Niemann HL, et al. National klinisk retningslinje for udvalgte sundhedsfaglige indsatser ved rehabilitering til patienter med type 2 diabetes. 2015.
  33. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218-27.
  34. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001;161(2):218-27.
  35. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288-94.
  36. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861-77.
  37. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058.
  38. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90.
  39. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-13.
  40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
  41. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-65.
  42. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-53.
  43. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG, investigators D. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69(11):2057-63.
  44. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-6.
  45. The Royal Australian College of General Practitioners. General practice management of type 2 diabetes: 2016-18 East Melbourne, Vic: RACGP; 2016 [Available from: https://www.racgp.org.au/download/Documents/Guidelines/Diabetes/2015diabetesmanagement.pdf.
  46. Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust. 2006;185(3):140-4.
  47. Sundhedsstyrelsen. Diabetiske fodsår - en medicinsk teknologivurdering. København: Sundhedsstyrelsen, Sundhedsdokumentation; 2011.
  48. Lund J. Diabetes i tandplejen. Tandlægebladet. 1999;103:318-25.
  49. Preshaw PM. Periodontal disease and diabetes. J Dent. 2009;37(8):S575-7.